gub70725

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Obesity in CKD: Treatment algorithm ca. 2026 from @NDTsocial @AKronbichler @SaynaNorouzi @rahaai
#Nephpearls

👉 https://t.co/MgVfk2bPDc

[Gunnar Henrik Heine @gunnar_heine]

May CETP inhibition with obicetrapib become the fifth pillar of nephroprotection?
@brendonneuen @KatherineTuttl8 @Badves @kidney_boy @hswapnil @NavTangri
https://t.co/hVR7TUW5rT

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

B cell maturation, treatment targets, and therapies ca. 2026 from @Kidney_Int @goKDIGO
#Nephpearls

👉 https://t.co/geFcmXY3Je

[Arkana Laboratories @arkanalabs]

We're excited to share a new research publication featuring @Tiff_Caza alongside collaborators from the NIH and Meharry Medical College, titled "Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy."

Read the publication here: https://t.co/m2Pz7eRTnt

#renalresearch #kidneyresearch #nephtwitter #membranous

[Nature Reviews Nephrology @NatRevNeph]

Clinical practice recommendations for the diagnosis and management of nephropathic cystinosis https://t.co/arb6X4SSX2

[ASN Publications @asnpublications]

#BasicResearch in #ASNKidney360 demonstrates that urinary phosphate may actively contribute to PKD progression. Higher phosphate levels were shown to accelerate cyst growth, activate fibrosis, and form calcium‑phosphate microcrystals in both mouse models and human PKD kidneys. https://t.co/HZdamL09Tk

[NDT @NDTsocial]

Albuminuria drives hyperlipidemia in patients with Alport syndrome

🔓https://t.co/CaCeGkmRWD

[NDT @NDTsocial]

SGLT2 inhibitors in CKD:

🤔are they really effective in all patients?

🆓 https://t.co/MacxDRPPYw

[NDT @NDTsocial]

Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index

https://t.co/Xil8z99DQa

[NDT @NDTsocial]

Optimal glucocorticoid therapy in lupus nephritis

https://t.co/e6SjmOrRpw

[AJKD @AJKDonline]

Association of Autosomal Dominant Polycystic Kidney Disease With Incident Aortic Dissection or Aneurysm

https://t.co/MrY4oO9wY7 (OPEN ACCESS)

[Kelly Haughton, MD @kidneydoctorpa]

IgA nephropathy progresses to kidney failure in up to 50% of patients within 10–20 years.

On March 29th, the NEJM published the final 24-month data from APPLAUSE-IgAN and the results change the treatment landscape.

Here’s what every nephrologist needs to know 🧵

Barratt J et al. NEJM 2026. DOI: 10.1056/NEJMoa2600743

[CKJ @CKJsocial]

SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art

https://t.co/gcfaOAsQHS

[CKJ @CKJsocial]

Bleeding prevention with desmopressin for allograft kidney biopsies: the double-blind randomized BRIDGE trial

https://t.co/V8x7XhauC7

[Dr sthanu subramanian @drsthanus]

Renal blood flow...

https://t.co/OQm77jxOvn

[AJKD @AJKDonline]

MINI REVIEW: A Practical Primer on How to Detect and Treat Depression in CKD

https://t.co/49CBFX7xtb (FREE)

@LParkerGregg1

[NEJM @NEJM]

In adults with type 1 diabetes and chronic kidney disease with albuminuria, the decrease in the urinary albumin-to-creatinine ratio was significantly greater with finerenone than with placebo. Full phase 3 FINE-ONE trial results and Research Summary: https://t.co/fitgDAJHR5

[CKJ @CKJsocial]

Older women with late-onset hypertension are at higher CKD risk than males

https://t.co/srLiW1ZxHk

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies ca. 2026 from @KidneyMed @JZRenalPath @IgAN_JBarratt @GlassockJ @DrRaymondHsu @Nephronpower @rahaai @SaynaNorouzi

📢 This paper is a very timely read for #NephMadness #Nephpearls

👉🆓 https://t.co/ATUOv7OAYQ

Nephmadness 👉 https://t.co/cqv1HK72v3

[ERA - European Renal Association @ERAkidney]

📊3/ SGLT2 Inhibitors: The RCTs that redefined kidney protection